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Background: Endothelial progenitor cells (EPC) are bone marrow-derived cells which can undergo differentiation into
endothelial cells and participate in endothelial repair and angiogenesis. Insulin facilitates this in vitro mediated by the
IGF-1 receptor. Clinical trials showed that the number of circulating EPCs is influenced by glucose control and EPC are
a predictor of cardiovascular death. To study direct effects of insulin treatment on EPCs in type 2 diabetes patients,
add-on basal insulin treatment was compared to an escalation of oral medication aiming at similar glucose control
between the groups.
Methods: 55 patients with type 2 diabetes (61.6±5.9 years) on oral diabetes medication were randomized in a 2:2:1
ratio in 3 groups. Patients were treated additionally with insulin glargine (n=20), NPH insulin (n=22) or escalated with
oral medication (n=13). Number of circulating EPC, EPC-outgrowth, intima media thickness, skin microvascular function
and HbA1c were documented at baseline and/or after 4 weeks and 4 months.
Results: HbA1c at baseline was, 7.3+/−0.7% in the oral group, 7.3+/−0.9% and 7.5+/−0.7% in the glargine and NPH
insulin respectively (p=0.713). HbA1c after 4 months decreased to 6.8+/−0.8%, 6.6+/−0.7% and 6.7+/−0.6%, in the oral,
glargine and NPH insulin group respectively (p=0.61). FACS analysis showed no difference in number of circulating EPC
between the groups after 4 weeks and 4 months. However, the outgrowth of EPCs as detected by colony forming
assay was increased in the NPH insulin and glargine groups (29.2+/−6.4 and 29.4+/− 6.7 units respectively) compared
to the group on oral medication (23.2+/−6.3, p=0.013) after 4 months of treatment. A significant decrease of IMT from
0.80mm (+/−0.14) at baseline to 0.76mm (+/−0.12) after 4 months could be observed in all patients only (p=0.03) with
a trend towards a reduction of IMT after 4 months when all patients on insulin treatment were compared to the oral
treatment group (p=0.06). Skin microvascular function revealed no differences between the groups (p=0.74).
Conclusion: The study shows that a 4-month treatment with add-on insulin significantly increases the outgrowth of
EPC in patients with type 2 diabetes mellitus.
Trial registration: (Clinical Trials Identifier: NCT00523393).
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Endothelial progenitor cells (EPCs) are immature bone
marrow-derived cells which undergo differentiation into
endothelial cells and participate in endothelial repair and
neoangiogenesis [1,2]. Clinical trials have shown that the
number of circulating EPC correlates with cardiovascu-
lar risk factors and is an independent predictor of car-
diovascular death [3,4]. Patients with diabetes type 1 and
2 have a reduced differentiation and function of EPC
in vitro [2,5,6].
Poor glycemic control and increase of glycated hemog-
lobin level is associated with an increase in the risk of
cardiovascular events [7], death [8,9] and for the devel-
opment of retinopathy or renal failure [9]. Data from
clinical trials imply that there might indeed be positive
effects of insulin therapy for the microvasculature [10]
while there seem to be limited effects on macrovascular
events in the ORIGIN and UKPDS trials [11,12]. Insulin
has previously been shown to have positive effects on
micro- and macrovascular function in experimental clin-
ical trials [13-16]. So far it is still not known, whether
the improvement of glucose control by any available
therapeutic strategy would have the same effects.
We were previously able to show that intensified insulin
therapy in poorly controlled diabetes leads to increased
numbers of CD34/CD133-positive progenitor cells that
can also be considered as precursors of EPC [17]. In
addition, we could show that insulin stimulates the in vitro
outgrowth of EPC and tube formation of adult endothe-
lial cells in an IGF-1 receptor dependent manner [18].
Hence, we hypothesized that insulin could improve the
outgrowth and number of circulating EPC independent
of glucose levels and thereby improve micro- or macro-
vascular function.
In this controlled trial it was therefore studied, whether
early addition of the long acting insulin analogue glargine
or NPH-insulin are capable of increasing the number
and differentiation of EPC compared to an escalation of
oral diabetes medication after 4 months of treatment.
In addition, the effects of insulin on microvascular
function as well as carotid intima media thickness were
studied in this randomized and controlled setting.
Research design and methods
73 patients with type 2 diabetes mellitus according to the
American Diabetes Association (ADA) criteria were en-
rolled in this prospective partially double-blind, random-
ized, three-arm mono-center trial (EudraCT-Nr: 2006-
006573-24). The study took place at the University Hos-
pital in Heidelberg, Germany. The main inclusion criteria
were treatment with oral diabetes medication, HbA1c
values > 6.5% and ≤ 9% and age between 35 and 70 years.
The primary endpoint of the trial was the relative change
of number of circulating EPC 4 weeks after start oftherapy compared to baseline as detected by FACS ana-
lysis. Secondary endpoints included: i) change of number
of circulating EPC 4 months after start of therapy com-
pared to baseline as detected by FACS analysis ii) change
in circulating EPC as detected by in vitro outgrowth iii)
intima media thickness iv) skin microvascular function (as
measured by laser Doppler perfusion upon heat stimula-
tion) v) long-term Glucose control (HbA1c) vi) short-term
Glucose control (fasting glucose). Glitazone and erythro-
poietin treatment was not permitted during the trial since
they were previously shown to influence EPC [19,20]. All
other oral antidiabetics as well as lipid and blood pressure
medications were allowed. Patients with statin treatment
were allowed to enter the study, yet statins were not added
during the 4 months of treatment due to known effect on
EPC [21]. Patients were randomized in a 1:2:2 ratio in 3
groups. The first treatment arm, consisting of patients re-
ceiving oral medication only, was treated openly. The
other two treatment arms, consisting of patients receiving
bedtime Insulin once daily in addition to existing oral
medication, were double blinded with glargine controlled
by NPH insulin. Randomisation of patients and monitor-
ing of the trial was performed according to the Standard
Operating Procedures from the Coordination Centre for
Clinical Trials (KKS) in Heidelberg. Ready to use NPH in-
sulin or glargine pens were packed and blinded by the
pharmacy of the University Hospital in Heidelberg accord-
ing to the randomization list. Anamnestic data (Table 1)
in addition to blood tests, and EPC quantification, were
documented/performed at the entry visit (visit 1), after
4 weeks (visit 2) and after 4 months (visit 3). Whereas in-
tima media thickness (IMT) and laser Doppler data were
documented/performed at the entry visit (visit 1) and after
4 months (visit 3).
On the day of visit 1, all patients randomized into one
of the groups receiving insulin were educated by a quali-
fied diabetes nurse or a physician on the following topics:
i) use of the insulin pen ii) injection techniques and dos-
age iii) hypoglycemia awareness and self treatment accord-
ing to the guidelines of the German Diabetes Association
[22]. Patients receiving oral medication were educated
concerning hypoglycemia awareness and self treatment
only. All patients entering this trial were supplied with a
device for blood glucose self monitoring (Accu-Check
Aviva®, Roche Diagnostics, Mannheim Germany). In pa-
tients randomized to receive either glargine or NPH in-
sulin, therapy was initiated with subcutaneous injection
of 4 international units at bedtime (usually around
10 p.m.). The dose was adjusted according to morning
fasting glucose levels using a titration scheme that was
handed out to each participant and aiming at fasting
glucose levels < 100 mg/dl. Patients on oral medication
were titrated to maximum dose using the following
combinations: metformin alone, DPP4-inhibitors alone,
Table 1 Baseline patient characteristics (visit 1)
Oral Glargine NPH Insulin all p
N 13 20 22 55
Age (yrs) 64.1 +/−4.1 60.1 +/−7.3 61.5 +/−5.0 61.6 +/−5.9 0.168
Gender (female/male;%) 6 (46)/7 (54) 7 (35)/13 (65) 9 (41)/13 (59) 22 (40)/33 (60) 0.810
BMI (kg/m2) 30.1 +/−5.4 32.7 +/−6.0 31.8 +/−5.2 31.7 +/−5.5 0.417
Diabetes duration (yrs) 6.2 +/−4.0 8.7 +/−6.6 9.8 +/−7.2 8.5 +/−6.4 0.286
Diabetic neuropathy (yes: n;%) 3 (23) 7 (37) 7 (35) 17 (33) 0.690
Diabetic nephropathy (yes: n;%) 0 3 (16) 2 (10) 5 (9) 0.324
Diabetic retinopathy (yes: n;%) 1 (8) 2 (10) 2 (10) 5 (9) 0.974
Systolic blood pressure (mmHg) 142.5 +/−14.3 145.1 +/−14.8 141.2 +/−12.9 142.9 +/−13.8 0.666
Diastolic blood pressure (mmHg) 79.6 +/−11.6 80.0 +/−10.2 79.1 +/−8.1 79.5 +/−9.6 0.964
HbA1c (%) 7.3 +/−0.7 7.3 +/−0.9 7.5 +/−0.7 7.4 +/−0.8 0.713
Fasting Glucose (mg/dl) 150.7 +/−41.1 166.8 +/−50.1 165.9 +/−38.9 162.6 +/−43.5 0.534
Serum Creatinin (mg/dl) 0.8 +/−0.2 0.9 +/−0.2 0.8 +/−0.2 0.8 +/−0.2 0.451
Triglycerides (mg/dl) 206.4 +/−131.2 208.9 +/−168.7 215.2 +/−110.7 210.8 +/−136.5 0.981
HDL-cholesterol (mg/dl) 48.5 +/−18.2 44.2 +/−10.0 44.2 +/−12.8 45.2 +/−13.3 0.599
LDL-cholesterol (mg/dl) 97.9 +/−30.0 88.1 +/−39.6 99.0 +/−27.5 94.8 +/−32.6 0.559
Hemoglobin (g/dl) 14.2 +/−1.0 13.6 +/−1.4 14.1 +/−1.3 13.9 +/−1.3 0.363
Leukocyte count /nl 6.3 +/−1.3 7.1 +/−2.2 7.5 +/−1.8 7.1 +/−1.9 0.187
Statins (yes: n;%) 7 (54) 14 (70) 10 (45) 31 (56) 0.271
Intima media thickness (mm) 0.83 +/−0.13 0.79 +/−0.13 0.79 +/−0.17 0.80 +/−0.14 0.737
Skin microvascular function (%) 555.1 +/−223.5 408.4 +/−216.5 455.7 +/−171.8 462.0 +/−205.5 0.132
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formin + sulfonylurea, metformin + glinides, acarbose
could be added to any of these combinations. All pa-
tients were provided with a diabetes diary at visit 1 in
which daily insulin dose, daily morning fasting glucose
self- measurements, one diurnal glucose profile weekly
(4 pre-meal values) and possible hypoglycemic episodes
were documented.
In order to discuss possible adverse events and to fur-
ther adjust treatment telephone calls of the investigators
with the participants took place 2 weeks and 2 months
after the entry visit.
The study complied with the Declaration of Helsinki
and was approved by the Ethics Committee of the Uni-
versity of Heidelberg (Ethic-Committee-No: AFm0-023/
2007); all patients entered the study according to the
guidelines after giving informed consent.
Laboratory parameters
On the day of all three visit time-points, ~ 20 ml of ven-
ous whole blood was drawn from the participants for
measurement of the following routine parameters: HbA1c,
glucose, hemoglobin, leukocyte count, erythrocyte count,
triglycerides, total cholesterol, HDL-cholesterol and LDL-
cholesterol, electrolytes (Sodium, Potassium), liver trans-
aminases (GOT, GPT), creatinine and urea. The samplesfor routine parameters were sent to the department of
clinical chemistry for analysis within 60 minutes after
blood was drawn.
Quantification of EPC using FACS-analysis
On the day of all three visits, ~ 10 ml of venous whole
blood was drawn from the participants and peripheral
blood mononuclear cells (pBMCs) were isolated by dens-
ity gradient centrifugation (lymphocyte separation; PAA
Laboratories, Pasching, Austria). EPCs were characterized
by flow cytometric analysis as previously described in de-
tail [17] using anti-CD34-FITC (Miltenyi Biotec GmbH,
Germany) and VEGFR-2-PE (R & D Systems, Minneapolis,
MN, USA). All measurements were normalized for auto
fluorescence and unspecific receptor binding using FITC-
(Pharmingen BD Biosciences) and PE-labeled isotype con-
trols. EPC were counted and analyzed using FACS Calibur
cell sorter (Becton Dickinson, Heidelberg Germany) and
Cell Quest Pro Software (Becton Dickinson, Heidelberg,
Germany) and expressed as a percentage of gated mono-
nuclear cells.
In vitro/ex vivo outgrowth of EPC
The outgrowth assay of EPCs in vitro was performed by
a standard method indicating clonogenic potential of cir-
culating EPCs as described in detail [3,23,24]. In brief,
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blood by density gradient centrifugation (lymphocyte sep-
aration; PAA Laboratories, Pasching, Austria). PBMCs
were preplated in tissue culture flasks (Sarstedt, Nuem-
brecht, Germany) in Medium199 (Invitrogen, Karlsruhe,
Germany) supplemented with 20% fetal calf serum (PAA
Laboratories) and penicillin/streptomycin/glutamine (Bio
Whittacker, Walkersville, MD, USA) to allow adhesion of
fast-adherent, differentiated cells. After 48 h, nonadherent
cells were counted, and 106 cells were plated on 24-cell
plates coated with 25 μg/mL fibronectin (Sigma, St. Louis,
MO, USA) and cultured in the same growth medium (see
above) without any additional growth factors. Medium
was changed after 3 days. Outgrowth of EPCs was quanti-
fied by counting of colony-forming units (CFUs).
Intima media thickness
Intima media thickness was detected as previously de-
scribed [25,26] at visits 1 and 3 by ultrasound in the
right and left common carotid artery approximately 1–
2 cm distal of the carotid bulb. Measurements were
taken at the far wall of the artery at 4 different loci and
in the end-diastolic phase of the heart cycle as docu-
mented by real time electrocardiogram.
Skin microvascular function using laser-doppler
Microvascular responsiveness was studied at visit 1 and
3 using laser Doppler perfusion measurement with Peri-
Flux System 5000 (Perimed, Järfälla, Sweden) upon heat
provocation as described in detail [27]. For this, 2 probes
were placed on the dorsum of the right foot. Basic capil-
lary perfusion was documented at 37°C skin temperature
for 10 minutes and at 44°C for additional 10 minutes to
study heat-provoked increase in perfusion as a marker of
microvascular function. The data were stored on a com-
puter and analyzed offline with signal processing soft-
ware (PeriSoft 2.50, Perimed). No current laser Doppler
instrument can provide absolute perfusion values. Mea-
surements are expressed as Perfusion Units (PU), which
are arbitrary.
Statistical Analysis
According to [17] and assuming a 0.01, 0.05, and 0.04 per
cent of peripheral mononuclear cells change in number of
circulating EPC after 4 weeks in the oral treatment group,
glargine, and NPH-insulin group, respectively, with a
common standard deviation of 0.04 randomisation of 75
patients was initially planned to achieve a power of 80%
with a two-sided global F test with alpha of 5%. The trial
was stopped after 73 patients, erroneously assuming that
the full sample size of 75 patients had been obtained. With
the patient number in the intention to treat (ITT) popula-
tion (n = 55) a power of 69.9% is reached under the initial
assumptions. Pair-wise group comparisons were plannedto be carried out according to the closed-testing principle
only after showing significance in the global test. The con-
firmatory analysis was primarily based on the ITT popula-
tion. If a patient discontinued the trial prematurely,
missing data were not replaced. In addition to the evalu-
ation of the ITT population, a per-protocol (PP) analysis
was performed including all randomized patients without
major protocol violations as sensitivity analysis. Secondary
variables were tabulated using appropriate descriptive
measures of the empirical distributions and descriptive
P values for treatment group comparisons.
For evaluation of the primary endpoint, a global F-test
was performed to test for differences between the three
groups. No pair-wise group comparisons could be carried
out. Secondary endpoints were analysed using descriptive
measures and graphical approaches. Homogeneity of treat-
ment groups was described by comparison of demographic
data and baseline values. Comparisons of binary data were
carried out using Pearson’s chi square test. In case of three
groups a global F-test was performed, two groups were
compared using the t-test. All additional evaluations were
described and fixed in the statistical analysis plan before
database closure. All analyses were performed using SAS®
9.2 (SAS Inc., Cary/NC, USA).
Results
10 out of 73 randomized patients stopped the trial be-
fore the first visit and therefore no values for EPC were
obtained. 3 patients discontinued before visit 2, 4 pa-
tients had missing values for EPC after 4 weeks and one
patient had a value of 0.00 and methodological bias at
visit 1. Therefore the intention to treat population in-
cluded 55 patients; 13 patients in the group with oral
medication; 20 patients receiving insulin glargine and 22
patients receiving NPH Insulin (Figure 1).
HbA1c at baseline was 7.3+/−0.7%, 7.3+/−0.9% and
7.5+/−0.7% in the oral, glargine and NPH insulin
group respectively and didn’t show any significant dif-
ference between the groups (p = 0.713; Table 1). The
levels of HbA1c after 4 months decreased to 6.8+/−0.8%,
6.6+/−0.7% and 6.7+/−0.6%, in the oral, glargine and NPH
insulin group respectively, without showing any significant
differences between groups (p = 0.614; Table 2).
No significant differences between the groups con-
cerning other metabolic parameters such as triglycerides,
LDL and HDL cholesterol, body mass index or blood
pressure could be observed. The number of reported ad-
verse events including hypoglycemia, and serious adverse
events did not differ between the groups.
A mean relative change of number of circulating EPC
4 weeks after start of therapy compared to baseline (as
detected by FACS) of 1.6 (+/−4.2) was obtained in the
intention to treat analysis set with median time between
visit 1 and 2 of 28 days. The mean relative change was
Figure 1 Study flow-chart.
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NPH insulin group and 1.8 (+/−3.8) in the oral group.
No statistically significant difference between the three
groups could be shown. The global F-test yielded a p-
value of 0.96. For that reason no post-hoc pairwise com-
parisons were performed. Analysis of the per protocol
set yielded similar results (p = 0.95) (Table 3).
After four months of treatment, a mean relative change
of 2.6 (+/−6.8) was obtained in the intention to treat ana-
lysis set with median time between visit 1 and 3 of
119 days. The mean relative change was 1.3 (+/−3.0) in
the glargine group, 3.1 (+/−7.4) in the NPH insulin group
and 3.8 (+/−9.5) in the oral group. No statistically signifi-
cant differences between the three groups could be shown
(p = 0.55, Table 3).Table 2 Patient characteristics after 4 months (visit 3)
Oral Glargin
N 13 20
BMI (kg/m2) 29.5+/−4.9 32.8+/−
HbA1c (%) 6.8+/−0.8 6.6+/−
Fasting Glucose (mg/dl) 139.5+/−36.0 136.5+
Serum Creatinin (mg/dl) 0.8+/−0.2 0.9+/−
Triglycerides (mg/dl) 166.5+/−93.8 178.7+
HDL-cholesterol (mg/dl) 52.6+/−17.4 46.1+/−
LDL-cholesterol (mg/dl) 106.2+/−31.6 85.7+/−
Hemoglobin (g/dl) 14.0+/−1.0 13.7+/−
Leukocyte count /nl 6.6+/−1.6 7.8+/−
Intima media thickness (mm) 0.82+/−0.11 0.74+/−
Skin microvascular function (%) 564.9+/−306.5 514.5+The number of colony forming units (CFUs) of EPC
as detected by in vitro outgrowth were significantly
higher in the NPH insulin group (29.2+/−6.4) and the
glargine group (29.4+/−6.7) compared to the oral group
(23.2+/−6.3) after 4 months (p = 0.013, Figure 2a).
When data from all patients receiving insulin (NPH
or glargine) were compared to those on oral medica-
tion a significant effect could be shown (p = 0.003,
Figure 2b).
Mean intima media thickness (IMT) at visit 1 was
0.80 mm (+/−0.14) with mean IMT of 0.79 mm
(+/−0.13), 0.79 mm (+/−0.17) and 0.83 mm (+/−0.13) in
the glargine, NPH insulin and control group, respectively
(p = 0.737, Table 1). At visit 3 mean IMT decreased to
0.76 mm (+/−0.12) with mean IMT of 0.74 mm (+/−0.10),
0.76 mm (+/−0.14) and 0.82 mm (+/−0.11) in the glargine,
NPH insulin and control group, respectively (p = 0.153,
Table 2) and therefore no statistical significance was
shown. However, when after 4 months IMT data from
all patients receiving insulin (NPH or glargine) were
compared to those on oral medication a trend towards
a reduction of IMT by insulin treatment could be docu-
mented (p = 0.06) indicating that in a longer trial or a
larger study population a significant result might have
been achieved (Figure 2c). Furthermore the decrease of
IMT from 0.80 mm (+/−0.14) at visit 1 to 0.76 mm
(+/−0.12) at visit 3 in all patients was statistically sig-
nificant (p = 0.03) indicating that all patients profited
from the intervention with respect to IMT.
Concerning the microvascular function of the skin at
visit 1 a mean of 462.0% (+/−205.5) increase upon heat
provocation could be observed, with a mean increase
of 408.4% (+/−216.5), 455.7% (+/−171.8) and 555.1%
(+/−223.5) in the glargine, NPH insulin and control
group, respectively (Table 1). At visit 3 a mean of 515.7%
(+/−283.8) increase upon heat provocation could be seene NPH Insulin all p
22 55
5.9 32.7+/−7.5 32.0+/−6.4 0.294
0.7 6.7+/−0.6 6.7+/−0.7 0.614
/−49.9 119.4+/−32.4 130.2+/−40.5 0.264
0.2 0.9+/−0.2 0.9+/−0.2 0.647
/−112.8 205.2+/−203.2 186.4+/−150.9 0.741
10.1 45.9+/−10.3 47.5+/−12.3 0.240
38.4 105.3+/−25.2 98.3+/−33.0 0.108
1.4 14.2+/−1.5 14.0+/−1.3 0.494
2.3 7.6+/−1.8 7.4+/−2.0 0.250
0.10 0.76+/−0.14 0.76+/−0.12 0.153
/−329.7 487.7+/−229.6 515.7+/−283.8 0.746
Table 3 Relative change of EPC between visit 1–2 and visit 1–3 as detected in FACS analysis
Oral Glargine NPH Insulin all p
EPC change visit 1-2
N 13 20 22 55 0.963
Mean +/− SD 1.8 +/−3.8 1.4 +/−4.1 1.5 +/−4.7 1.6 +/−4.2
Median (Q1, Q3) 0.4 (−0.1, 1.0) −0.2 (−0.7, 0.9) −0.1 (−0.5, 0.8) 0.1 (−0.5, 0.9)
EPC change visit 1-3
N 13 19 21 53 0.551
Mean +/− SD 3.8 +/−9.5 1.3 +/−3.0 3.1 +/−7.4 1.3 +/−3.0
Median (Q1, Q3) 1.0 (−0.4, 1.8) 0.2 (−0.7, 2.6) 0.2 (−0.2,1.7 0.2 (−0.4, 1.8)
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(+/−229.6) and 564.9% (+/−306.5) in the glargine, NPH
insulin and control group, respectively (Table 2). No sig-
nificant difference between the three groups could be
observed.
18 adverse events were reported. 5 in the glargine group,
7 in the NPH insulin group and 6 in the control group. Of
those there were 2 mild hypoglyceamias reported in the
glargine group. No adverse effects was categorized as
severe.
Discussion
This is the first study investigating the effects of add-on
basal insulin treatment in a direct comparison to oral dia-
betes medication on endothelial progenitor cells in pa-
tients with type 2 diabetes mellitus. Our current data
showed that a 4-month treatment with insulin glargine or
NPH insulin significantly increases the ex vivo differenti-
ation of EPCs in patients with type 2 diabetes mellitus,
compared to an escalation of the oral antidiabetic therapy
without additional insulin treatment. These findings are in
agreement with our previously published data showing
that insulin glargine and human insulin stimulate the
clonogenic potential of EPCs in vitro [18]. However, no
significant change in the numbers of circulating EPCs
could be observed within the 4 months suggesting that
there are no direct biological effects of insulin on the
number of circulating EPC at least within the docu-
mented 4 months treatment in this study. These results
are in agreement with a study by Fadini et al. where sig-
nificant changes after adding insulin analogues in a
crossover design could only be shown after 6 months of
treatment [28]. As we previously described in a pilot
study [17], a very recent study has shown an increase
on circulating EPCs and outgrowth of CFUs in patients
with long-standing uncontrolled type 2 diabetes receiv-
ing an intensified antidiabetic treatment. Yet this study
did not compare different treatment strategies [29],
which was the aim of our current study. Our data indi-
cate that insulin treatment has a possible early effect on
the functionality of EPCs while changes in numbers ofcirculating EPC could require more time and a long
term improvement of metabolic control.
It has been previously shown that hyperglycemia re-
duces survival and impairs the function of EPCs in vitro
[30] and that in patients with type 2 diabetes mellitus the
levels of circulating EPCs are closely related to glycaemic
control [31]. Poor glyceamic control is known to play a
key role in the properties of circulating EPCs and several
mechanisms seem to be involved in that, including ad-
vanced glycation end products formation [32] and reduced
activity of silent information regulator 1 (SIRT1) and in-
creased synthesis of platelet-activating factor (PAF) [33].
All 3 groups in this study achieved a significant decrease
of HbA1c. However as aimed for, there were no significant
differences concerning the HbA1c levels between the
groups at baseline and after 4 months suggesting that the
observed effects on EPC outgrowth did not depend on
glycemic control but rather on direct insulin effects as we
were previously able to show in vitro [18].
Since glargine and NPH insulin have a different struc-
ture and biologic activity, we assumed that the different
pharmacokinetic properties could translate into different
effects on EPCs. We were previously able to show that
insulin stimulates the clonogenic potential of EPCs by
IGF-1 receptor-dependent signaling [18] and it is known
that insulin glargine has a 6-fold increased affinity for
the IGF-1 receptor [34]. Yet the glargine metabolite gly-
A21-insulin, that has been shown to have similar affinity
to the IGF-1 receptors as human insulin [34], comprises
most of the available substance in vivo [35]. Accordingly
and in line with our previous in vitro data [18] we found
no differences between NPH insulin and glargine on the
function or the number of circulating EPCs. Furthermore
no differences concerning other metabolic parameters as
cholesterol levels, body mass index, skin microvascular func-
tion and in terms of safety profile including hypoglycemia
could be observed.
IMT has been widely used as a surrogate parameter in
primary intervention studies of cardiovascular risk reduc-
tion [36]. Previous studies have shown that patients with
type 1 diabetes mellitus without macrovascular disease
Figure 2 (See legend on next page.)
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Figure 2 Comparison of the number of colony forming units (CFUs) and intima media thickness between groups. (a) Analysis shows
significantly higher numbers in the NPH insulin group (29.2+/−6.4) and the glargine group (29.4+/− 6.7) compared to the oral group
(23.2+/−6.3) after 4 months of treatment (p = 0.013). (b) Comparison of number of CFUs from all patients receiving insulin (NPH or glargine)
to those on oral medication showing a significant effect after 4 months of treatment (p = 0.003). (c) Comparison of IMT from all patients
receiving insulin (NPH or glargine) to those on oral medication. A trend towards a reduction of IMT after 4 months of insulin treatment could
be documented (p = 0.06)
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IMT [37]. Moreover a previous study in middle-aged
healthy people found a significant correlation between
EPC number and IMT [38]. We were not able to detect
any significant changes in carotid intima media thickness
throughout the study between the 3 study groups. How-
ever, interestingly when IMT data from all patients receiv-
ing insulin (NPH or glargine) were compared to those on
oral medication 4 months after baseline, a trend towards a
reduction of IMT by insulin treatment could be docu-
mented indicating that in a trial with a larger study popu-
lation a significant result might have been achieved. This
hypothesis can be further supported by data recently pub-
lished showing that in people with cardiovascular disease
and/or CV risk factors, insulin glargine used to target
normoglycemia modestly reduced carotid IMT progres-
sion [39].
Remarkably, at least a trend for a reduction of IMT
was seen in patients treated with insulin while there
were no effects of NPH insulin or glargine treatment on
microvascular function. These data in our randomized
and controlled setting contrasts previously published re-
sults from type 2 diabetes patients subjected to glycemic
improvement by insulin or oral treatment [40-42]. It will
have to be clarified, whether this is due to differences in
study design or a consequence of methodological as-
pects. Yet, we believe that our data suggests that there
could be only marginal effects of insulin treatment or
improvement of glucose control since we did not see ef-
fects after 4 months of treatment even when patients in
the study were pooled (data not shown).
Limitations of the study certainly include the relatively
high rate of drop-outs which led to a reduction of the
power of the study as mentioned above. Drop-out rates
were relatively high mainly because patients that were ran-
domized to receive insulin treatment would then decide
to leave the study probably because they initially believed
they would enter the oral medication arm although they
were thoroughly instructed that this was a randomized
trial. Additionally it should be noted that our current clin-
ical study was based on a methodological paper that has
been previously published [18]. Since then, different ap-
proaches have been used to culture and quantify EPC
therefore the term EPCs should be used with caution
since most commonly used methods for isolating EPCs in
culture have been found to generate a mixed populationof cells [43] However, we were previously able to show
that the cells in our outgrowth assay carry established pro-
genitor cell antigens, have a distinct influence on tube for-
mation in vitro and incorporate into vascular structures
and therefore should be considered angiogenic progeni-
tors [18]. Even though the goal of this study was to de-
tect possible differences on EPCs between patients on
guideline-suggested diabetes oral medication or add-on
therapy with insulin glargine and NPH insulin, the fact
that in most cases the diabetes medication in the oral
group was escalated could be a limitation since many
oral antidiabetics have been known to have at least
some effects on EPCs [44]. It is in most cases though
not clear, whether these effects are direct drug effects
or if they are a result of improved glycemic control.
Furthermore several anti-diabetic and cardioprotective
agents including metformin and rosuvastatin have been
shown to have beneficial effects on endothelial cell via-
bility, regeneration and apoptosis [45]. Even newer anti
diabetic medication as the dipeptidyl peptidase-4 in-
hibitor Saxagliptin has been shown to improve the
function of circulating pro-angiogenic cells from type 2
diabetic patients [46]. Glitazone treatment and a change
in lipid lowering therapy, that were known at the time
the study was designed to influence EPC, were not
allowed in this study.
The results of this study are independent of glycemic
control but nevertheless the functional meaning of an
improved EPC differentiation still needs to be clarified.
Conclusion
The study shows that a 4-month treatment with insulin
glargine or NPH insulin significantly increased the out-
growth of EPCs in patients with type 2 diabetes mellitus
compared to patients who received an escalation of the
oral diabetes treatment only. The observed effects on
EPC outgrowth did not depend on glycemic control but
rather on direct insulin effects. We therefore believe that
this study provides valuable information regarding pleio-
tropic effects of insulin that could possibly influence vas-
cular homeostasis and outcomes.
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